in vivo News and Research

RSS

Researchers reveal Prozac reactions to increase serotonin level

The response time to antidepressants, such as Prozac, is around three weeks. The adaptation mechanisms of the neurons to antidepressants has, until now, remained enigmatic. In particular, the researchers have revealed, for the first time, a sequence of reactions caused by Prozac at the neuron level, which contributes to an increase in the amounts of serotonin, a chemical "messenger" essential to the brain, and deficient in depressive individuals.

17 Sep 2010

NMS Labs launches method for K2 drug metabolites detection in urine

Of growing concern to public health officials and law enforcement is that routine drug testing cannot detect the use of the popular and highly intoxicating new drugs K2 and Spice. NMS Labs now has a full menu of tests that can detect the use of the designer chemicals present in these products, sold as incense or legal highs. A few weeks ago, NMS Labs launched a blood test to detect a range of these laboratory-designed synthetic drugs.

16 Sep 2010

Researchers develop infected tissue model for Aganocide compounds

Two common and important human pathogens, P. aeruginosa and S. aureus, are implicated in many clinical diseases of the eye and skin, including keratitis and impetigo, respectively. Infections with their associated toxins can result in the destruction of underlying tissue.

16 Sep 2010

Researchers identify mechanism to reduce pathogenic effect of bacillus bacteria

A European-Asian collaboration of scientists, notably including CNRS, the Institut Pasteur in Paris, the Institut Pasteur Korea in Seoul (IP Korea/Equipe Avenir Inserm and the Université de Toulouse have identified ten virulence genes of the tubercle bacillus. The inactivation of these genes lessens the pathogenic effects of the bacillus.

16 Sep 2010

Cell-enriched primary renal cells improve survival and augment kidney function in CKD rodents

Tengion, Inc., a leader in regenerative medicine, announced today the publication of a key study in the American Journal of Physiology Renal Physiology by researchers at Tengion. In the study, rodents with chronic kidney disease (CKD) were treated with healthy kidney cells to catalyze the regeneration of functional kidney tissue and delay disease progression, as evidenced by extended survival, improved kidney filtration, and reduced severity of kidney tissue pathology.

14 Sep 2010

AB SCIEX, University of Melbourne join to develop drug metabolism studies of biopharmaceuticals

AB SCIEX, a global leader in life science analytical technologies, and the University of Melbourne today announced a joint technology development project to improve drug metabolism studies of biopharmaceuticals.

13 Sep 2010

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Trevena Inc., the leader in the discovery and development of G-protein coupled receptor biased ligands, today announced that its scientists are presenting two posters featuring compelling preclinical pharmacology data on TRV120027 at the 14th Annual Heart Failure Society of America Meeting being held September 12-15, 2010 in San Diego.

13 Sep 2010

Genetic misfolding of neuroligins protein may lead to autism spectrum disorders: Research

An international team of scientists, led by researchers at the University of California, San Diego, has identified misfolding and other molecular anomalies in a key brain protein associated with autism spectrum disorders.

13 Sep 2010

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18.

13 Sep 2010

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for radezolid at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) conference.

13 Sep 2010

NanoBio Corporation to present Nanoemulsion Phase I clinical trial data at ICAAC Conference

NanoBio Corporation today announced it will present data from two separate Phase 1 clinical trials at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Boston, Mass. from Sept. 12-15.

13 Sep 2010

Numerate awarded new contract by Defense Threat Reduction Agency

Numerate, Inc. announced today that it has been awarded a new three-year contract by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense, to adapt its pioneering small-molecule drug design platform to the rapid design and optimization of drugs against biowarfare agents.

10 Sep 2010

Caliper launches toolkit for direct co-registration of images from multiple preclinical imaging modalities

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today introduced software and accessory items to enable the direct co-registration of images from multiple preclinical imaging modalities.

9 Sep 2010

Cellectis acquires assets of Cyto Pulse Sciences

Cellectis, the French genome engineering specialist, has announced today that it has acquired all the assets of Cyto Pulse Sciences Inc., a US-based company specializing in the development, manufacture and commercialization of electroporation technology and equipment.

9 Sep 2010

Zyngenia completes $15M Series A financing extension from NEA

Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.

8 Sep 2010

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Trius Therapeutics, Inc. announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15.

8 Sep 2010

Researchers discover tolerance mechanism in chronic morphine treatment

Researchers from Mount Sinai School of Medicine have discovered a major mechanism underlying the development of tolerance to chronic morphine treatment. The discovery may help researchers find new therapies to treat chronic pain, and reduce tolerance and side effects associated with morphine use. The findings are published in the July 20th issue of Science Signaling.

8 Sep 2010

Bruker launches Icon desktop MRI systems at 2010 World Molecular Imaging Congress

At the 2010 World Molecular Imaging Congress in Kyoto, Bruker Corporation today announces the introduction of the Icon™, a new easy-to-use 1 Tesla desktop MRI scanner that combines simplicity with compact dimensions, in order to bring preclinical magnetic resonance imaging (MRI) within reach for a broader range of molecular imaging laboratories.

7 Sep 2010

Medtronic announces international launch of Resolute Integrity Stent System

Medtronic, Inc. (NYSE: MDT), announces the CE (Conformite Europeene) mark and international launch of the Resolute Integrity Stent System for the treatment of coronary artery disease, a leading cause of death and poor quality of life.

7 Sep 2010

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Bioorganic & Medicinal Chemistry Letters on the anti-tumor activity of RX-8243 and its analogues.

3 Sep 2010

in vivo News and Research

Researchers reveal Prozac reactions to increase serotonin level

NMS Labs launches method for K2 drug metabolites detection in urine

Researchers develop infected tissue model for Aganocide compounds

Researchers identify mechanism to reduce pathogenic effect of bacillus bacteria

Cell-enriched primary renal cells improve survival and augment kidney function in CKD rodents

AB SCIEX, University of Melbourne join to develop drug metabolism studies of biopharmaceuticals

Scientists to present preclinical pharmacology data on TRV120027 at Heart Failure Society of America Meeting

Genetic misfolding of neuroligins protein may lead to autism spectrum disorders: Research

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Rib-X Pharmaceuticals presents preclinical data of radezolid drug at ICAAC Conference

NanoBio Corporation to present Nanoemulsion Phase I clinical trial data at ICAAC Conference

Numerate awarded new contract by Defense Threat Reduction Agency

Caliper launches toolkit for direct co-registration of images from multiple preclinical imaging modalities

Cellectis acquires assets of Cyto Pulse Sciences

Zyngenia completes $15M Series A financing extension from NEA

Trius Therapeutics announces presentations from drug development programs at 50th ICAAC

Researchers discover tolerance mechanism in chronic morphine treatment

Bruker launches Icon desktop MRI systems at 2010 World Molecular Imaging Congress

Medtronic announces international launch of Resolute Integrity Stent System

Rexahn Pharmaceuticals publishes research article on RX-8243 anti-tumor activity

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News